Neurofit, an artificial intelligence (AI) company specializing in brain disease diagnosis and treatment, announced on the 29th that it had submitted a securities report to the Financial Services Commission and is entering into full-scale public offering procedures.
The total number of shares that Neurofit is offering is 2 million, with a target offering price range of 11,400 won to 14,000 won, and a total offering amount of 22.8 billion won to 28 billion won. A demand forecast for institutional investors will be conducted from July 4 to 10, and general subscription will be conducted on the 15th and 16th. The lead underwriter is Mirae Asset Securities.
Neurofit is a specialized company that researches and develops brain imaging analysis solutions and therapeutic medical devices based on artificial intelligence (AI) technology. It was founded in 2016 by Neurofit co-CEOs Bin Jun-gil and Kim Dong-hyun, who developed the next-generation neuronavigation system at the Gwangju Institute of Science and Technology (GIST).
By developing Neurofit Aqua, Neurofit Scale Pet, Neurofit Aqua AD, and Neurofit Teslab, the company is expanding its business from brain disease diagnosis to the therapeutic market. Among these, Neurofit Aqua AD provides all the brain imaging analysis functions required in the process of administering anti-amyloid antibody treatment. As the market for Alzheimer's disease treatment such as Rekembi and Keysunra is opening, Neurofit's technology that can monitor new drug administration eligibility and side effects such as cerebral microhemorrhage and edema is receiving more attention from the industry.
A Neurofit official explained, “The technology is also being used in clinical trials for Alzheimer’s disease treatments that are still under development,” and “As we are entering the treatment market in various ways, not just the imaging diagnosis market, we will be able to expand our business into the companion diagnosis area if the treatment undergoing clinical trials is launched.”
Bin Jun-gil, Co-CEO of Neurofit, said, “Neurofit has begun expanding from imaging diagnosis to the treatment field, and is producing real results in the brain disease market based on various business models such as participating in the process of developing new drugs.” He added, “As brain imaging analysis technology related to treatments is attracting attention, we plan to accelerate collaboration with global big pharma and actively attack the market.”
- See more related articles
You must be logged in to post a comment.